U.S and Germany Start 8,000 Person COVID-19 mRNA Vaccine Trials

BioNTech - 1 minute read

  • First U.S participants dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine
  • German trials started at the end of April
  • Full use of Pfizer’s vaccine manufacturing facilities as they outsource production of their current drugs
  • Capacity for production of 100s of millions of vaccines

“It is encouraging that we have been able to leverage more than a decade of experience in developing our mRNA platforms to initiate a global clinical trial in multiple regions for our vaccine program in such a short period.

Ugur Sahin – CEO, BioNTech

10 months ago from BioNTech's press release via